Latest 10-K annual reports

Newton Golf Company's 2024 10-K filing reveals significant revenue growth driven by new product lines, but also highlights substantial net losses and concerns about the company's ability to continue as a going concern.

American Shared Hospital Services (ASHS) reports a 32.9% increase in total revenue for 2024, primarily driven by growth in its direct patient services (retail) segment.

PLAYSTUDIOS, Inc. files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information, correct the number of outstanding shares, and add disclosure regarding a Rule 10b5-1 trading arrangement.

Creative Medical Technology Holdings files an amendment to its annual report to include a clawback policy in compliance with Nasdaq listing rules.

Spire Global files an amended 10-K acknowledging substantial doubt about its ability to continue as a going concern due to financial losses and the uncertain closing of its maritime business sale to Kpler Holding SA.

ReShape Lifesciences Inc. details its 2024 financial performance and strategic initiatives, including a pending merger with Vyome Therapeutics and an asset sale to Ninjour Health International, while navigating challenges in the weight-loss market.

IR-Med, Inc. files its 10-K report for 2024, highlighting ongoing development of its PressureSafe and DiaSafe devices amid financial challenges and efforts to secure additional funding.

Jubilant Flame International reports continued losses for the fiscal year ended February 28, 2025, while focusing on technical support services for the nutrition industry.

Domo, Inc. reports a slight revenue decline for fiscal year 2025 while emphasizing a transition to a consumption-based service model and cost management.

ESH Acquisition Corp.'s 2024 10-K filing reveals an extension of its business combination deadline, significant redemptions, and ongoing efforts to identify a suitable target.

Bioxytran's Form 10-K reveals ongoing losses and dependence on future financing for its drug development programs, including BXT-25 and ProLectin-Rx, despite recent subsidiary acquisition and IND approvals.

IX Acquisition Corp.'s 10-K filing reveals substantial doubt about its ability to continue as a going concern as it seeks to finalize a business combination with AERKOMM Inc.

Bitmine Immersion Technologies files an amendment to its 10-K report to provide more detailed financial statements and expand disclosures on accounting policies.

AccuStem Sciences outlines its plans to commercialize its MSC and StemPrintER diagnostic tests while reporting a net loss for the year ended December 31, 2024.

Charles & Colvard reports a decrease in net sales for fiscal year 2024 amid economic challenges, while focusing on operational efficiency and strategic initiatives.

CareCloud files an amendment to its 2024 Annual Report to correct a typographical error in the Audit Opinion and include new consents and certifications.

National Presto Industries amends its original 10-K filing to include previously omitted exhibits related to a voting trust agreement and insider trading policy.

Alchemy Investments Acquisition Corp 1 reports a net income for 2024 but acknowledges substantial doubt about its ability to continue as a going concern due to its upcoming business combination deadline and liquidity challenges.

Falcons Beyond Global's 10-K filing reveals strategic realignments, including an asset-efficient approach in destinations and growth in creative services, but also raises substantial doubt about the company's ability to continue as a going concern due to liquidity challenges.

Firefly Neuroscience's latest 10-K filing highlights its focus on AI-driven neuroscientific solutions and commercial launch of the BNA Platform, while also acknowledging substantial doubt about its ability to continue as a going concern.

dMY Squared Technology Group files its 10-K, restating prior financials due to errors in calculating Class A common stock redemption value and misuse of trust account funds.

Reviva Pharmaceuticals' 10-K filing highlights positive Phase 3 trial results for brilaroxazine in schizophrenia and outlines the company's strategy for potential FDA approval.

EOS Inc. filed Amendment No. 5 to its Form 10-K to clarify risks associated with operating in China and Hong Kong, including regulatory and legal uncertainties.

BlackBerry Limited announces its fiscal year 2025 results, highlighting a net loss of $79.0 million and providing revenue guidance for fiscal year 2026.

Tevogen Bio Holdings Inc. details its financial standing, development strategy, and regulatory landscape in its annual 10-K filing, emphasizing its ExacTcell technology and lead product candidate, TVGN 489.

NovaBay Pharmaceuticals is evaluating strategic options, including a potential dissolution, after selling its Avenova and wound care assets.

Cyclacel Pharmaceuticals' 2024 10-K filing reveals a company in strategic transition, focusing on its plogosertib program while addressing financial constraints through cost reductions and exploring strategic alternatives.

Dawson Geophysical reports a net loss for 2024 but highlights improved margins and strategic cost management amid fluctuating oil and gas prices.

RH's 10-K filing details the company's capital stock structure, shareholder rights, and provisions designed to deter hostile takeovers.

Serve Robotics files an amendment to its original 10-K report to include management's report on internal control over financial reporting, which was inadvertently omitted.